The differences in the epidemiology and predictors of death between Candidemia acquired in intensive care units and other hospital settings

Internal Medicine

Volumn 54, Issue 23, 2015, Pages 3009-3016

  Li, Chen ^a   Wang, Hao ^a   Yin, Mei ^a   Han, Hui ^a   Yue, Jin Feng ^a   Zhang, Fan ^a   Shan, Ti Chao ^a   Guo, Hai Peng ^a   Wu, Da Wei ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Candidemia; Death; Epidemiology; Intensive care unit; Predictors

Indexed keywords

AMPHOTERICIN B; CREATINE; FLUCONAZOLE; GLUCOSE; ITRACONAZOLE; POTASSIUM; SODIUM; VORICONAZOLE; ANTIFUNGAL AGENT;

ADULT; ANTIFUNGAL RESISTANCE; APACHE; ARTICLE; ARTIFICIAL VENTILATION; CANDIDA; CANDIDEMIA; DEATH; FEMALE; HEMATOLOGIC MALIGNANCY; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NEUTROPENIA; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RISK FACTOR; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SOLID TUMOR; THROMBOCYTE COUNT; TREATMENT OUTCOME; AGED; BACTEREMIA; CHINA; CLINICAL TRIAL; EPIDEMIOLOGY; HOSPITAL; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOGENICITY; PROGNOSIS;

AGED; ANTIFUNGAL AGENTS; BACTEREMIA; CANDIDA; CANDIDEMIA; CHINA; DRUG RESISTANCE, FUNGAL; FEMALE; HOSPITALS; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84948949015     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.54.3744     Document Type: Article

References (41)

1. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 48: 1695-1703, 2009.
2. Ostrosky-Zeichner L, Kullberg BJ, Bow EJ, et al. Early treatment of candidemia in adults: a review. Med Mycol 49: 113-120, 2011.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309-317, 2004.
4. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 38: 311-320, 2004.
5. Almirante B, Rodriguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43: 1829-1835, 2005.
6. Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 32 (Suppl 2): S87-S91, 2008.
7. Pfaller M, Neofytos D, Diekema D, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008. Diagn Microbiol Infect Dis 74: 323-331, 2012.
8. Mikulska M, Del Bono V, Ratto S, et al. Occurrence, presentation and treatment of candidemia. Expert Rev Clin Immunol 8: 755-765, 2012.
9. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36: 1-53, 2010.
10. Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6: 21, 2006.
11. Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 37: 1612-1618, 2009.
12. Zhang XB, Yu SJ, Yu JX, Gong YL, Feng W, Sun FJ. Retrospective analysis of epidemiology and prognostic factors for candidemia at a hospital in China, 2000-2009. Jpn J Infect Dis 65: 510-515, 2012.
13. Playford EG, Nimmo GR, Tilse M, Sorrell TC. Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999-2008. J Hosp Infect 76: 46-51, 2010.
14. Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients. Ann Pharmacother 41: 568-573, 2007.
15. Aliyu SH, Enoch DA, Abubakar II, et al. Candidaemia in a large teaching hospital: a clinical audit. QJM 99: 655-663, 2006.
16. Uzun O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 32: 1713-1717, 2001.
17. Colombo AL, Guimarães T, Silva LR, et al. Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol 28: 570-576, 2007.
18. Viudes A, Pemán J, Cantón E, Ubeda P, López-Ribot JL, Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 21: 767-774, 2002.
19. Bassetti M, Trecarichi EM, Righi E, et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 58: 325-331, 2007.
20. Chang RW, Jacobs S, Lee B. Predicting outcome among intensive care unit patients using computerised trend analysis of daily Apache II scores corrected for organ system failure. Intensive Care Med 14: 558-566, 1988.
21. Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 26: 1793-1800, 1998.
22. Pfaller MA, Andes D, Diekema DJ, et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 13: 180-195, 2010.
23. Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 70: 330-343, 2011.
24. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 14: 164-176, 2011.
25. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts: Third informational supplement. Rex JH, Alexander BD, Andes D, et al, Eds. CLSI, Wayne, PA, 2008: 1-28.
26. Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol 25: 60-64, 2004.
27. Marik PE, Lipman J. The definition of septic shock: implications for treatment. Crit Care Resusc 9: 101-103, 2007.
28. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503-535, 2009.
29. Rodloff C, Koch D, Schaumann R. Epidemiology and antifungal resistance in invasive candidiasis. Eur J Med Res 16: 187-195, 2011.
30. De Luca C, Guglielminetti M, Ferrario A, Calabr M, Casari E. Candidemia: species involved, virulence factors and antimycotic susceptibility. New Microbiol 35: 459-468, 2012.
31. Bassetti M, Molinari MP, Mussap M, Viscoli C, Righi E. Candidaemia in internal medicine departments: the burden of a rising problem. Clin Microbiol Infect 19: E281-E284, 2013.
32. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 38: 65-69, 2011.
33. Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54: 1110-1122, 2012.
34. Charles PE, Doise JM, Quenot JP, et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med 29: 2162-2169, 2003.
35. Sipsas NV, Lewis RE, Tarrand J, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115: 4745-4752, 2009.
36. Bougnoux ME, Kac G, Aegerter P, d’Enfert C, Fagon JY; Candi-Rea Study Group. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med 34: 292-299, 2008.
37. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43: 25-31, 2006.
38. Zilberberg MD, Kollef MH, Arnold H, et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 10: 150, 2010.
39. Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz Pérezde Pipaón M, Hernández-Caballero C, Lepe-Jiménez JA. Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. J Antimicrob Chemother 68: 206-213, 2013.
40. Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 30: 2051-2058, 2002.
41. Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 287: 345-355, 2002.